Panel participants share an optimistic outlook for integrating new innovations, tacking community-level challenges, and more.

The past few years have been a roller coaster ride for M&A in pharma and biotech. After the highs of the pandemic came ...

Ash Shehata from KPMG discusses how investors are feeling about the pharma and life sciences industry heading into 2025.

Pharmaceutical companies’ direct-to-patient (DTP) programs have recently sparked conversations and criticism in fear of their potential to “cut out” or influence physicians, the truth is that ...

Cary Claiborne, CEO, Adial Pharmaceuticals, discusses promising results of the AD04-13 study in patients with Alcohol Use Disorder PE: Can you elaborate on the key design elements of the AD04-13 study ...

Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and endoscopic response rates in patients with Crohn disease. The FDA has ...

Cigna Healthcare, the health benefits division of The Cigna Group, announced a new offering in collaboration with Progyny, Inc that will allow employers to offer fertility coverage that is more ...

The company revealed plans to increase the usage of AI in pharma at JP Morgan’s healthcare conference in San Francisco. Over the past two years, the life sciences industry has seemingly fully embraced ...

The technology is part of a larger platform that provides a variety of AI-powered services. As people in the industry become more comfortable with the technology, AI is being used to find potential ...

Niktimvo marks the first FDA-approved therapy targeting CSF-1R to address inflammation and fibrosis in chronic graft-versus-host disease. The FDA has approved Incyte’s and Syndax’s Niktimvo ...

The digital transformation of the pharmaceutical industry continues to provide innovative ways to improve the clinical research process. With the growing importance of strategies like real-time data ...

John Hood, CEO, Endeavor BioMedicines discusses partnering with advocacy groups to increase awareness of clinical trials for idiopathic pulmonary fibrosis. PE: Are there any ongoing collaborations ...